GeneOne Life Science Inc (011000) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneOne Life Science Inc (011000) has a cash flow conversion efficiency ratio of -0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.61 Billion ≈ $-2.45 Million USD) by net assets (₩55.36 Billion ≈ $37.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneOne Life Science Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how GeneOne Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GeneOne Life Science Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
GeneOne Life Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneOne Life Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Broad Capital Acquisition Corp Unit
NASDAQ:BRACU
|
0.008x |
|
Brand Group (M.G) Ltd
TA:BRND
|
0.030x |
|
Land and Houses Freehold and Leasehold Property Fund
BK:LHPF
|
0.004x |
|
SKILLCAST GROUP LS -001
F:K9I
|
N/A |
|
Nsys Co. Ltd.
KQ:333620
|
0.014x |
|
Optomed PLC
HE:OPTOMED
|
-0.052x |
|
Springwater Special Situations Corp
NASDAQ:SWSS
|
-0.007x |
|
Selic Corp Public Company Limited
BK:SELIC
|
0.030x |
Annual Cash Flow Conversion Efficiency for GeneOne Life Science Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of GeneOne Life Science Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of GeneOne Life Science Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩85.61 Billion ≈ $58.01 Million |
₩-16.06 Billion ≈ $-10.88 Million |
-0.188x | +3.82% |
| 2023-12-31 | ₩111.49 Billion ≈ $75.55 Million |
₩-21.74 Billion ≈ $-14.74 Million |
-0.195x | -46.78% |
| 2022-12-31 | ₩181.47 Billion ≈ $122.98 Million |
₩-24.11 Billion ≈ $-16.34 Million |
-0.133x | -462.98% |
| 2021-12-31 | ₩205.45 Billion ≈ $139.23 Million |
₩-4.85 Billion ≈ $-3.29 Million |
-0.024x | +85.39% |
| 2020-12-31 | ₩98.51 Billion ≈ $66.76 Million |
₩-15.92 Billion ≈ $-10.79 Million |
-0.162x | -206.09% |
| 2019-12-31 | ₩24.06 Billion ≈ $16.31 Million |
₩-1.27 Billion ≈ $-860.67K |
-0.053x | +78.64% |
| 2018-12-31 | ₩29.41 Billion ≈ $19.93 Million |
₩-7.27 Billion ≈ $-4.93 Million |
-0.247x | -123.54% |
| 2017-12-31 | ₩36.54 Billion ≈ $24.76 Million |
₩-4.04 Billion ≈ $-2.74 Million |
-0.111x | +68.00% |
| 2016-12-31 | ₩35.85 Billion ≈ $24.30 Million |
₩-12.39 Billion ≈ $-8.40 Million |
-0.346x | -1850.57% |
| 2015-12-31 | ₩39.44 Billion ≈ $26.73 Million |
₩778.50 Million ≈ $527.58K |
0.020x | +116.49% |
| 2014-12-31 | ₩34.73 Billion ≈ $23.54 Million |
₩-4.16 Billion ≈ $-2.82 Million |
-0.120x | -20.95% |
| 2013-12-31 | ₩23.71 Billion ≈ $16.07 Million |
₩-2.35 Billion ≈ $-1.59 Million |
-0.099x | -- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more